Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.81 |
| ▸ | GAA | P10253 | 3/20 | 0.72 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.72 |
| ▸ | NPC1 | O15118 | 5/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.65 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.64 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 3/20 | 0.63 |
| ▸ | HTT | P42858 | 3/20 | 0.63 |
| ▸ | GLA | P06280 | 2/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.63 |
| ▸ | RAB9A | P51151 | 4/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5246151 | 0.95 | KDM4E (0.78) | KDM4EGAAHDAC3NPC1CYP1A2 | |
| SCHEMBL6928579 | 0.94 | KDM4E (0.76) | KDM4EGAAHDAC3NPC1CYP1A2 | |
| SCHEMBL3077089 | 0.90 | KDM4E (0.74) | KDM4EGAAHDAC3NPC1CYP1A2 | |
| Hydrochloric Acid SCHEMBL31169755 | 0.88 | KDM4E (0.72) | KDM4EGAAHDAC3NPC1CYP1A2 | |
| SCHEMBL6127192 | 0.88 | KDM4E (0.89) | KDM4EGAAHDAC3NPC1CYP1A2 | |
| SCHEMBL18197872 | 0.85 | KDM4E (0.84) | KDM4EGAAHDAC3NPC1CYP1A2 | |
| SCHEMBL27189083 | 0.85 | GAA (0.65) | KDM4EGAAHDAC3NPC1CYP1A2 | |
| SCHEMBL18906066 | 0.85 | KDM4E (0.83) | KDM4EGAAHDAC3NPC1CYP1A2 | |
| SCHEMBL1864971 | 0.84 | GAA (0.85) | KDM4EGAAHDAC3NPC1CYP1A2 | |
| SCHEMBL27447873 | 0.84 | HDAC3 (1.00) | KDM4EGAAHDAC3NPC1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013144737-A2 | NOVEL 3,5-DISUBSTITUED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF C-MET PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2013-10-03 | — | — | WO | disclosed |
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-2038289-A2 | THIENO-[2,3-D]PYRIMIDINE AND THIENO-PYRIDAZINE COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| WO-2007124181-A2 | THIENO-[2,3-D]PYRIMIDINE AND THIENO-PYRIDAZINE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | KDM4E 128/4885GAA 551/4885HDAC3 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.